IBL Healthcare Limited, a wholly owned subsidiary of Indrayani Biotech Limited has invested in M/s. Kniss Laboratories Private Limited by subscribing to 54,68,934 Equity shares of the Company of face value of Rs. 10/- each on preferential allotment/private placement basis in two tranches. Thus, it becomes subsidiary to the Wholly owned subsidiary, IBL Healthcare Limited.

Kniss Laboratories Private Limited is a pharma manufacturing unit certified by ISO 9001-2008 for quality compliance and awarded good manufacturing practice license by state drug authority of India.

Over the period of time, KNISS has established a solid foundation of trust in the customers' minds, delivering high quality Products uncompromisingly. The company has a constant endeavour to enhance the standards by implementing the best practices in processes and systems, and by continuous improvements in the systems and quality of their products and services.

A belief in providing quality healthcare products at affordable prices driven by the highest standards of ethics and human values can only hold the company in good stead. KNISS today aims to be a global Pharma player, backed by an excellent manufacturing, marketing and logistics network.

Presently, the company manufactures and markets a wide range of pharmaceutical and nutraceutical products for various therapeutic groups.

The entrepreneurial nature of the company continues with additional foray into propriety herbal medicines, a fast expanding, rapidly growing sector. Combining knowledge from the ancient system of Ayurveda, and modern-day testing techniques, KNISS has developed a wide range of products for a variety of indications. The Company also undertakes contract manufacturing for other companies.

On the export front, the Company has started exporting its products to the countries in East Europe, Middle East and South East Asia. In the coming years, major thrust will be given to broaden the spectrum of export activities.